Current status of home blood pressure monitoring in Asia: Statement from the HOPE Asia Network

On behalf of the HOPE Asia Network

Research output: Contribution to journalReview articlepeer-review

43 Citations (Scopus)


Hypertension represents a major burden in Asia, with a high prevalence rate but poor level of awareness and control reported in many countries in the region. Home blood pressure monitoring has been validated as an accurate and reliable measure of blood pressure that can help guide hypertension treatment as well as identify masked and white-coat hypertension. Despite its benefits, there has been limited research into home blood pressure monitoring in Asia. The authors reviewed the current evidence on home blood pressure monitoring in Asia, including but not limited to published literature, data presented at congresses, and national hypertension management guidelines to determine the current utilization of home blood pressure monitoring in clinical practice in the region. Public policies to enable greater access to home blood pressure monitoring and its use in clinical care would add considerably to improving hypertension outcomes in Asia.

Original languageEnglish
Pages (from-to)1192-1201
Number of pages10
JournalJournal of Clinical Hypertension
Issue number11
Publication statusPublished - 2017 Nov

Bibliographical note

Funding Information:
CH Chen has received honoraria as a member of a speaker’s bureau for Pfizer. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. R Divinagracia has received honoraria as a member of speakers’ bureaus for Bayer, Novartis, and Pfizer. K Kario has received research grants from A&D Co., Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Fukuda Denshi, Medtronic, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Omron Healthcare, Otsuka, Takeda, and Teijin Pharma Co.; and honoraria from Daiichi Sankyo, Omron Healthcare, and Takeda. S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, GlaxoSmithKline, Pfizer, and Servier; and travel, accommodation and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, and Pfizer. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JG Wang has received research grants from Bayer, Pfizer, and Phillips; and lecture and consulting fees from Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, and Servier. L Wong has received honoraria from Bristol-Myers Squibb and Pfizer. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article.

Funding Information:
This statement on blood pressure measurement is supported by the World Hypertension League.

Publisher Copyright:
©2017 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Current status of home blood pressure monitoring in Asia: Statement from the HOPE Asia Network'. Together they form a unique fingerprint.

Cite this